Abstract: Aspects presented herein may improve UE positioning by providing enhanced resource patterns that may reduce positioning latency and resource overhead for the UE positioning. In one aspect, a transmitter divides a reference signal associated with UE positioning into a plurality of sub-bandwidths, each of the plurality of sub-bandwidths being associated with a comb offset. The transmitter transmits, to a receiver, the reference signal via the plurality of sub-bandwidths. In another aspect, a receiver receives a configuration to measure a reference signal associated with UE positioning. The receiver receives, from a transmitter, the reference signal via a plurality of sub-bandwidths, each of the plurality of sub-bandwidths being associated with a comb offset.

Abstract: Methods, systems, and devices for wireless communications are described in which a user equipment (UE) may be configured to monitor a set of beams, and may request an update to a monitoring configuration based on a position of the UE, an orientation of the UE, a rate of change of the position or orientation, or any combinations thereof. In some cases, the position or orientation information of the UE may include information for a current time period, predictive information for one or more future time periods, other information, or any combinations thereof. The UE may transmit a beam monitoring request to a base station for an updated monitoring configuration, such as a subset of a set of configured beams or an identified scan angle to be monitored by the UE.

Abstract: Certain aspects of the present disclosure relate to methods and apparatus relating to a long uplink burst channel design. In certain aspects, the method includes determining, based on a hopping pattern, a first set of frequency resources available for transmitting uplink control information (UCI) within a first portion of a transmission time interval (TTI) and a second set of frequency resources available for transmitting UCI within a second portion of the TTI. The method also includes transmitting the UCI using the determined first set of frequency resources and the second set of frequency resources.

Abstract: Aspects of the disclosure provide techniques for waveform indication for physical uplink control channel (PUCCH) transmissions. A network entity may provide an indication of a waveform type, such as CP-OFDM, DFT-s-OFDM, or other suitable waveform type, for a PUCCH format to a user equipment (UE). The UE may then communicate a PUCCH with the network entity using the waveform type for the PUCCH format.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive a system information message including first system information for the UE; receive, after receiving the system information message, a system information update message indicating a change to at least a portion of the first system information; determine whether the change applies to one or more capabilities of the UE; and selectively acquire second system information based at least in part on whether the change applies to the one or more capabilities of the UE. Numerous other aspects are provided.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive a wakeup signal (WUS) monitoring configuration that identifies one or more first WUS monitoring parameters associated with short discontinuous reception (DRX) cycle operation of the UE and one or more second WUS monitoring parameters associated with long DRX cycle operation of the UE. The UE may monitor for a WUS based at least in part on the WUS monitoring configuration. Numerous other aspects are provided.

Abstract: Methods, systems, and devices for wireless communication are described. A communication device, such as, a base station and a UE may support transmitting and receiving information bits according to one or more index modulation schemes. For example, the communication device may support conveying information bits using a reference signal index modulation scheme, which uses reference signals transmissions using particular resources or reference signal sequences, or both, to convey the information bits. The communication device may improve reference signal resource usage by supporting a multi-mode reference signal index modulation scheme, which utilizes all reference signal resources to convey the information bits. By using the multi-mode reference signal index modulation scheme, the communication device may, as a result, include features for improvements to conveying information bits, among other benefits.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: The invention provides methods of introducing diversity into antibody molecules comprising introducing or substituting at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and FW region sequences comprising diverse amino acid sequences are also described. These polypeptides regions, herein referred to as 3+CDR3+, that form the gist of the invention contribution described herein provide a flexible and simple source of sequence diversity that can be used as a source for expressing and identifying diverse antibodies or antigen binding polypeptides. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.

Abstract: A method of filling trenches such as a DT cell with silicon is described that involves a vapor-liquid-solid (VLS) mechanism. First, a thin film of Si is grown on the trench sidewalls. Seed metal such as Au, Ni or Ni alloy is deposited on the sidewalls by an electroless plating process. A thermal treatment is then used to reflow the metal to a liquid state art the trench bottom. A Si precursor gas is applied to grow a single whisker that fills the trench. Silicon overgrowth is removed by an etch or CMP step. The method can also be applied to filling a via hole with silicide. In this case the seed metal is Ti, Co, or Ni which is reflowed by a thermal treatment. A silicon source gas like SiCl4 is combined with H2 to grow the silicide layer. This method is especially useful in forming seamless fill layers.